Dupixent Hits Another Milestone: EU Green Light for Chronic Skin Condition

rekt_but_not_broke · 2025-12-01T16:57:57+00:00

Sanofi and Regeneron's Dupixent has been approved by the European Commission for treating moderate-to-severe chronic spontaneous urticaria, marking the first targeted drug for this condition in over a decade. Dupixent has seen significant financial success, with projected revenues of €22 billion by 2030.

rekt_but_not_broke

2025-12-01 16:57:57

Abstract generation in progress

Sanofi and Regeneron just got the European Commission’s thumbs up for Dupixent (dupilumab) to treat moderate-to-severe chronic spontaneous urticaria (CSU) in patients 12+. This is actually a big deal—it’s the first targeted drug approved for CSU in the EU in over a decade.

What’s CSU?

Basically, it’s a type II inflammatory skin condition that causes sudden, intense hives and swelling that antihistamines alone can’t control. Dupixent works as an add-on therapy for patients who don’t respond well to standard treatments.

The Numbers

Dupixent is now approved for 8 inflammatory diseases in the U.S. and 7 in the EU. Here’s the money part: in the first 9 months of 2025, Dupixent raked in €11.47 billion globally (up 22.7% YoY). Sanofi is projecting it’ll hit around €22 billion by 2030.

Regenerative’s cut? $4.24 billion in collaboration revenues from Sanofi in 9M 2025, up 27.8% YoY.

What’s Next?

The companies are currently seeking FDA approval for Dupixent to treat allergic fungal rhinosinusitis (AFRS)—that decision’s expected by Feb 28, 2026. If approved, it’d be Dupixent’s 9th U.S. indication.

Bottom line: Dupixent is basically printing money for both companies, and this EU nod just unlocked another revenue stream.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.